<DOC>
	<DOCNO>NCT02815540</DOCNO>
	<brief_summary>The investigator propose study effect cannabidiol ( CBD ) cardiac electrical function autonomic nervous system child Dravet syndrome ( DS ) Lennox-Gastaut syndrome ( LGS ) , CBD administer artisanal oil obtain state dispensary source . The intent begin assess potential risk benefit therapy vulnerable patient population characterize effect CBD EKG finding , heart rate variability occurrence seizure .</brief_summary>
	<brief_title>The Effects Cannabidiol ( CBD ) Electrical Autonomic Cardiac Function Children With Severe Epilepsy</brief_title>
	<detailed_description>Specific Aims/Study Objectives This pilot study explore effect cannabidiol ( CBD ) autonomic cardiac function child Dravet syndrome ( DS ) Lennox-Gastaut syndrome ( LGS ) CBD administer artisanal oil . This achieve address follow specific aim . Aim # 1 : To determine effect CBD cardiac function 30 child DS LGS . This primary aim study : The effect CBD cardiac function 30 child DS LGS assess use 15-lead electrocardiogram ( EKG ) 24-hour Holter monitor . Investigators hypothesize alteration ventricular repolarization heart rate variability EKG Holter monitoring , respectively , take CBD 4-8 week , compare participant take CBD . Note : The follow aim secondary primary outcome goal assess effect CBD cardiac function . Aim # 2 : To assess sign symptom dysautonomia presence absence CBD . Signs symptoms dysautonomia include parental perception body temperature , skin color hand foot , sweat , pupil size , flushing , feed issue , heart rate , strong emotion , constipation , urination bowel movement issue , irritability . These sign symptom collect use previously-established dysautonomia survey . Investigators hypothesize change qualitative assessment sign symptom dysautonomia take CBD 4-8 week , compare participant take CBD . Aim # 3 : To determine effect CBD occurrence seizure . The number seizures child obtain CBD assess use 7-day seizure diary ( Seizure tracker ) . Caregivers record number seizures 7-day period prior CBD administration , repeat seizure track receive CBD 4-8 week . Change seizure number compare pre- post-CBD administration . Investigators hypothesize study participant low seizure count CBD compare n't take CBD . Study Design Methodology Study Design : Thirty patient DS LGS go register take medical cannabis ( cannabidiol , CBD ) state Minnesota offer opportunity participate study . If consent obtain , patient guardian ask complete questionnaire develop study document observable sign symptom dysautonomia , complete seizure diary 7 day prior initially receive CBD . Each participant also 15-lead electrocardiogram ( EKG ) wear 24-hour Holter monitor , non-invasive measure cardiac function , prior administer CBD . The EKG 24-hour Holter monitor interpret cardiac electrophysiologist review heart rate variability parameter . The dysautonomia questionnaire , seizure diary cardiac measurement repeat 4-8 week subject stable regimen CBD . This time-frame base availability subject schedule clinic visit , also great 5 half-lives previously report CBD ( apparent half-life , 21 hour , ( 15 ) ) . Steady-state level achieve 5 half-lives drug dosing , thus expect steady-state concentration . Subjects already stable regimen CBD , yet plan stop take CBD point reason , also eligible participate . The parent guardian complete dysautonimia questionnaire seizure diary ( research staff available help question ) , patient 15-lead EKG 24-hour Holter monitor still CBD . The subject come back 4-8 week last dose CBD assessment repeat CBD . This time frame base availability subject schedule clinic visit well substantially great 5 half-lives CBD , standard wash-out period pharmacological study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lennox Gastaut Syndrome</mesh_term>
	<mesh_term>Epilepsies , Myoclonic</mesh_term>
	<criteria>Diagnosed Dravet syndrome LennoxGastaut syndrome Patients plan obtain medical cannabadiol Patients aleady take medical cannabadiol planning stop take Patients without diagnosis Dravet syndrome LennoxGastaut syndrome</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>